|
307 Companies |
|
474 Products |
|
474 Products |
|
223 Mechanisms of Action |
|
25 Trials |
|
4911 News |
|
| «12...1415161718192021222324...9899» |
- Trial primary completion date: Microsphere Localization Using PET/MRI or PET/CT in Patients Following Radioembolization (clinicaltrials.gov) - Jan 17, 2016
P=N/A, N=60, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Oct 2015 --> Oct 2016
- Trial completion, Enrollment change, Trial primary completion date: A Multi-Center Group to Study Acute Liver Failure in Children (clinicaltrials.gov) - Jan 16, 2016
P=N/A, N=158, Completed, Sponsor: University of Pittsburgh
Trial primary completion date: Oct 2015 --> Oct 2016 Recruiting --> Completed | N=300 --> 158 | Trial primary completion date: Aug 2015 --> Dec 2015
- CC-700C / TCM Biotech
Enrollment change, Trial withdrawal: The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III) (clinicaltrials.gov) - Jan 16, 2016
P3, N=0, Withdrawn, Sponsor: TCM Biotech International Corp.
Recruiting --> Completed | N=300 --> 158 | Trial primary completion date: Aug 2015 --> Dec 2015 N=598 --> 0 | Not yet recruiting --> Withdrawn
- spironolactone / Generic mfg., eplerenone / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date, Adverse events: Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis; a Study of Efficacy and Side Effects (clinicaltrials.gov) - Jan 16, 2016
P2, N=0, Withdrawn, Sponsor: Emma Nilsson
N=598 --> 0 | Not yet recruiting --> Withdrawn N=150 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Mar 2016 --> Oct 2015
- | Trial completion: Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis (clinicaltrials.gov) - Jan 16, 2016
P3, N=60, Completed, Sponsor: Bambino Gesù Hospital and Research Institute
N=150 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Mar 2016 --> Oct 2015 Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: GRADS Sarc: Genomic Research in Sarcoidosis (clinicaltrials.gov) - Jan 16, 2016
P=N/A, N=368, Completed, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Feb 2015 --> Jun 2015
- Pegasys (pegylated interferon ? -2a) / Roche
Enrollment open, Trial primary completion date: Optimized Treatment and Regression of HBV-induced Liver Fibrosis (clinicaltrials.gov) - Jan 15, 2016
P4, N=400, Recruiting, Sponsor: Beijing Friendship Hospital
Recruiting --> Completed | Trial primary completion date: Feb 2015 --> Jun 2015 Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2015 --> Dec 2016
- Trial completion, Enrollment change, Trial primary completion date: Transcutaneous Electrical Acupoint Stimulation(TEAS) for Hepatic and Renal Dysfunction After Pneumoperitoneum (clinicaltrials.gov) - Jan 15, 2016
P=N/A, N=168, Completed, Sponsor: Zhihong LU
Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Completed | N=30 --> 168 | Trial primary completion date: May 2015 --> Dec 2015
- Enrollment open: EFIGRO: Effect of Exercise on Hepatic Fat in Overweight Children (clinicaltrials.gov) - Jan 15, 2016
P=N/A, N=160, Recruiting, Sponsor: Basque Country University
Recruiting --> Completed | N=30 --> 168 | Trial primary completion date: May 2015 --> Dec 2015 Not yet recruiting --> Recruiting
- |||| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Trial completion, Enrollment change: EFFECTII: A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients (clinicaltrials.gov) - Jan 15, 2016
P2, N=223, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=80 --> 223
- | Besivo (besifovir) / Gilead, LG Chem, Ildong
Trial completion: Bioequivalence Study to Compare the Pharmacokinetics of Besifovir in Healthy Adult Volunteers (clinicaltrials.gov) - Jan 15, 2016
P1, N=24, Completed, Sponsor: IlDong Pharmaceutical Co Ltd
Active, not recruiting --> Completed | N=80 --> 223 Not yet recruiting --> Completed
- | Enrollment open, Trial primary completion date: ViaDUCT: Can Vitamin D Supplementation Improve Hepatitis C Cure Rates (clinicaltrials.gov) - Jan 12, 2016
P3, N=160, Recruiting, Sponsor: Jim Flood
Not yet recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2015 --> Apr 2016
- |||| Legalon (silibinin) / Mylan
Trial completion, Trial primary completion date: Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) (clinicaltrials.gov) - Jan 12, 2016
P2, N=99, Completed, Sponsor: University of Malaya
Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2015 --> Apr 2016 Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Dec 2015
- Trial completion: Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis (clinicaltrials.gov) - Jan 12, 2016
P=N/A, N=90, Completed, Sponsor: Mayo Clinic
Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Dec 2015 Active, not recruiting --> Completed
- Myalept (metreleptin) / Novelion
Clinical protocol, Enrollment closed, Trial primary completion date: Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy (clinicaltrials.gov) - Jan 11, 2016
P2, N=23, Active, not recruiting, Sponsor: University of Michigan
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> May 2016
- DC Bead (E7040) / Eisai, Boston Scientific
Trial completion, Enrollment change, Trial primary completion date: LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed (clinicaltrials.gov) - Jan 8, 2016
P2, N=1, Completed, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> May 2016 Recruiting --> Completed | N=20 --> 1 | Trial primary completion date: Nov 2011 --> May 2011
- | SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Trial completion: Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Jan 7, 2016
P1/2, N=35, Completed, Sponsor: Singapore Clinical Research Institute
Recruiting --> Completed | N=20 --> 1 | Trial primary completion date: Nov 2011 --> May 2011 Active, not recruiting --> Completed
- ||||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Trial completion: Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination (clinicaltrials.gov) - Jan 6, 2016
P3, N=558, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Trial initiation date: Injection of Cyanoacrylate+Lipiodol vs Cyanoacrylate+Lauromacrogol in Gastric Varices (clinicaltrials.gov) - Jan 6, 2016
P=N/A, N=96, Completed, Sponsor: Shanghai Zhongshan Hospital
Active, not recruiting --> Completed Recruiting --> Completed | Initiation date: Apr 2013 --> Oct 2013
- Trial initiation date: Resveratrol and Human Hepatocyte Function in Cancer (clinicaltrials.gov) - Jan 5, 2016
P1/2, N=80, Not yet recruiting, Sponsor: University of Louisville
Recruiting --> Completed | Initiation date: Apr 2013 --> Oct 2013 Initiation date: Dec 2015 --> Dec 2016
- ||| Zepsun (donafenib) / Suzhou Zelgen
Trial completion, Metastases: Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Jan 5, 2016
P1b, N=106, Completed, Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Initiation date: Dec 2015 --> Dec 2016 Recruiting --> Completed
- Trial completion: Evaluation of EV1000™/volumeView™ for Cardiac Output Monitoring in Liver Transplantation (clinicaltrials.gov) - Dec 29, 2015
P=N/A, N=28, Completed, Sponsor: Samsung Medical Center
Recruiting --> Completed Recruiting --> Completed
- Phase classification: Spectroscopy With Surface Coils and Decoupling (clinicaltrials.gov) - Dec 29, 2015
P1, N=582, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Completed Phase classification: P=N/A --> P1
- Trial completion, Enrollment change: Safety Study of Modified Vaccinia Virus to Cancer (clinicaltrials.gov) - Dec 29, 2015
P1, N=26, Completed, Sponsor: David Bartlett
Phase classification: P=N/A --> P1 Active, not recruiting --> Completed | N=36 --> 26
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., floxuridine / Generic mfg.
Trial completion, Enrollment change: Safety Study of Oxaliplatin and 5-fluorouracil Followed by FUDR for Unresectable Colorectal Liver Metastases (clinicaltrials.gov) - Dec 29, 2015
P1, N=14, Completed, Sponsor: David Bartlett
Active, not recruiting --> Completed | N=36 --> 26 Active, not recruiting --> Completed | N=24 --> 14
- |||| Olysio (simeprevir) / J&J, Medivir
Trial completion, Combination therapy: An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Dec 29, 2015
P2, N=63, Completed, Sponsor: Janssen-Cilag International NV
Active, not recruiting --> Completed | N=24 --> 14 Active, not recruiting --> Completed
- Trial completion, Enrollment change: Quantitative Real-time Ultrasound Elastography for Characterisation of Liver Tumors (clinicaltrials.gov) - Dec 25, 2015
P=N/A, N=196, Completed, Sponsor: University Hospital Dubrava
Active, not recruiting --> Completed Recruiting --> Completed | N=159 --> 196
- cisplatin / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date, Combination therapy: SBRT + TACE for Primary Hepatocellular Carcinoma (clinicaltrials.gov) - Dec 25, 2015
P=N/A, N=0, Withdrawn, Sponsor: University of Pittsburgh
Recruiting --> Completed | N=159 --> 196 N=12 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Jun 2014 --> Dec 2015
- | Trial completion, Trial primary completion date: CaSSY: Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms (clinicaltrials.gov) - Dec 25, 2015
P3, N=261, Completed, Sponsor: University of Pittsburgh
N=12 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Jun 2014 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Jun 2013 --> Dec 2013
- Trial primary completion date, Adherence: Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV Coinfection (clinicaltrials.gov) - Dec 23, 2015
P=N/A, N=75, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Active, not recruiting --> Completed | Trial primary completion date: Jun 2013 --> Dec 2013 Trial primary completion date: Jan 2016 --> Jun 2016
- Trial completion: STANDAREA: Monitoring of Encephalopathy in Cirrhotic Patients Admitted in Intensive Care (clinicaltrials.gov) - Dec 23, 2015
P=N/A, N=224, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Trial primary completion date: Jan 2016 --> Jun 2016 Active, not recruiting --> Completed
- || Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS
Trial primary completion date: Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C (clinicaltrials.gov) - Dec 23, 2015
P=N/A, N=3000, Recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Trial primary completion date: Feb 2017 --> May 2016
- sorafenib / Generic mfg.
Trial primary completion date, Metastases: A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective (clinicaltrials.gov) - Dec 21, 2015
P1/2, N=48, Active, not recruiting, Sponsor: Thomas Jefferson University
Trial primary completion date: Feb 2017 --> May 2016 Trial primary completion date: Sep 2015 --> Sep 2016
- cixutumumab (IMC A12) / Eli Lilly
Trial primary completion date, Metastases: Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer (clinicaltrials.gov) - Dec 17, 2015
P1, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Trial completion: Effect of Rifaximine on Sleep Disorders in Patients Suffering From Hepatic Encephalopathy (clinicaltrials.gov) - Dec 17, 2015
P=N/A, N=15, Completed, Sponsor: Centre Hospitalier Universitaire Saint Pierre
Trial primary completion date: Dec 2015 --> Jun 2016 Recruiting --> Completed
- Biomarker, Enrollment change, Trial primary completion date: Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases (clinicaltrials.gov) - Dec 16, 2015
P=N/A, N=500, Recruiting, Sponsor: Baylor College of Medicine
Recruiting --> Completed N=45 --> 500 | Trial primary completion date: Dec 2015 --> Dec 2016
- | valacyclovir / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I) (clinicaltrials.gov) - Dec 16, 2015
P1, N=31, Completed, Sponsor: VA Office of Research and Development
N=45 --> 500 | Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Completed | N=125 --> 31 | Trial primary completion date: Dec 2015 --> Jul 2015
- Trial primary completion date: Polygen Defi-Alpha: Genetic Polymorphisms Study in Children With Alpha-1 Antitrypsin Deficiency, Included in the DEFI-ALPHA Cohort (clinicaltrials.gov) - Dec 15, 2015
P=N/A, N=400, Recruiting, Sponsor: Hospices Civils de Lyon
Recruiting --> Completed | N=125 --> 31 | Trial primary completion date: Dec 2015 --> Jul 2015 Trial primary completion date: Nov 2015 --> Dec 2016
- Trial primary completion date: Mechanisms Involved in the Benefits of an Exercise Programme in Patients With Cirrhosis (clinicaltrials.gov) - Dec 15, 2015
P=N/A, N=30, Completed, Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Trial primary completion date: Nov 2015 --> Dec 2016 Trial primary completion date: Sep 2011 --> Jun 2012
- | emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion: Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States (clinicaltrials.gov) - Dec 15, 2015
P2, N=24, Completed, Sponsor: Gilead Sciences
Trial primary completion date: Sep 2011 --> Jun 2012 Active, not recruiting --> Completed
- Trial completion: Community-based Hepatitis B Interventions for Hmong Adults (clinicaltrials.gov) - Dec 12, 2015
P=N/A, N=1500, Completed, Sponsor: University of California, Davis
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- Euvax B (recombinant hepatitis B vaccine) / LG Chem
Enrollment open, Trial initiation date, Trial primary completion date: Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda (clinicaltrials.gov) - Dec 12, 2015
P4, N=132, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Enrolling by invitation --> Completed Not yet recruiting --> Recruiting | Initiation date: Aug 2015 --> Nov 2015 | Trial primary completion date: Feb 2017 --> Jun 2017
- ||||||| ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Trial completion: ASTRAL-3: Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection (clinicaltrials.gov) - Dec 12, 2015
P3, N=558, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting | Initiation date: Aug 2015 --> Nov 2015 | Trial primary completion date: Feb 2017 --> Jun 2017 Active, not recruiting --> Completed
- ||||||| sofosbuvir/velpatasvir / Generic mfg.
Trial completion: ASTRAL-4: Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis (clinicaltrials.gov) - Dec 12, 2015
P3, N=268, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial primary completion date: Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease (clinicaltrials.gov) - Dec 11, 2015
P=N/A, N=33, Recruiting, Sponsor: Virginia Commonwealth University
Active, not recruiting --> Completed Trial primary completion date: May 2015 --> May 2016
- ND-L02-s0201 / Nitto Denko, BMS
Enrollment closed: Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4) (clinicaltrials.gov) - Dec 11, 2015
P1, N=25, Active, not recruiting, Sponsor: Nitto Denko Corporation
Trial primary completion date: May 2015 --> May 2016 Recruiting --> Active, not recruiting
- ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection (clinicaltrials.gov) - Dec 11, 2015
P2, N=68, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- | Ruzasvir (MK-8408) / Merck (MSD)
Trial completion, PK/PD data, Enrollment change: Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003) (clinicaltrials.gov) - Dec 11, 2015
P1, N=22, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Completed Active, not recruiting --> Completed | N=40 --> 22
- Trial primary completion date, Biopsy: Non Invasive Assessment of Liver Fibrosis in Children: Comparison of ShearWave Elastography, Fibrotest and Liver Biopsy (clinicaltrials.gov) - Dec 10, 2015
P=N/A, N=80, Recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed | N=40 --> 22 Trial primary completion date: Nov 2015 --> Sep 2016
- | Hepabig-gene (lenvervimab) / GC Biopharma
Enrollment closed, Trial primary completion date: A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients (clinicaltrials.gov) - Dec 10, 2015
P2, N=40, Active, not recruiting, Sponsor: Green Cross Corporation
Trial primary completion date: Nov 2015 --> Sep 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Jun 2016